ArticleDiscover oncology2025
LncRNA ADAMTS9-AS1 regulates the proliferation, migration, and invasion of esophageal cancer cells via miR-575/ CADM2.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LncRNA DLGAP1-AS2 promotes ESCC progression and indicates unfavorable prognosis via the miR-101-3p/EZH2 axis.Discover oncology · 2026Article
- Integrative Analysis of IGFL2‑AS1 and BRCA1 Expression in Esophageal Cancer: An Experimental and Bioinformatics‑Based Study.Iranian biomedical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) ranks among the most lethal malignant neoplasms globally, representing a significant risk to public health.
objectivesThis study investigates the impact of lncRNA ADAMTS9-AS1 on the function of ESCC cells by targeting and regulating miR-575/CADM2 axis. MATERIALS AND
methodsqPCR was employed to assess the expression of ADAMTS9-AS1, miR-575, and CADM2 in ESCC tissues and cells. Chi-square test was utilized to examine the association between ADAMTS9-AS1 and clinical indicators. Cox model was applied to identify risk factors of poor prognosis, and survival curves were generated using the Kaplan-Meier method. Furthermore, the effects of overexpressing ADAMTS9-AS1 alone and in conjunction with miR-575 were analyzed in ESCC cell lines, utilizing CCK-8 assays to evaluate cell proliferation, and Transwell assays to assess cell invasion and migration capabilities.
resultsThe study revealed that in ESCC tissues and cell lines, the expression levels of ADAMTS9-AS1 and CADM2 were decreased and exhibited a positive correlation, whereas the miR-575 was elevated and demonstrated a negative correlation with both molecules. The expression of ADAMTS9-AS1 was associated with TNM staging and lymph node metastasis, serving as a risk factor for poor prognosis. Overexpression ADAMTS9-AS1 could inhibit miR-575 expression, and suppress cellular proliferation, migration, and invasion. However, this inhibitory effect was reversed when miR-575 was concurrently overexpressed.
conclusionThe targeting effect of ADAMTS9-AS1 on miR-575/CADM2 changes in ESCC cell function and further mediated the progression of ESCC. ADAMTS9-AS1 has the potential to be a prognostic biomarker and molecular target for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.